Strong Buy
Average AnalystStrong Buy
Top AnalystSlightly Bearish
Stock Target AdvisorStrong Buy
Average UserUSD 1.62
-0.05 (-2.99%)
USD 0.43B
2.93M
USD 10.00(+517.28%)
Based on the Allogene Therapeutics Inc stock forecast from 4 analysts, the average analyst target price for Allogene Therapeutics Inc is USD 10.00 over the next 12 months. Allogene Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Allogene Therapeutics Inc is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Allogene Therapeutics Inc’s stock price was USD 1.62. Allogene Therapeutics Inc’s stock price has changed by -16.06% over the past week, -25.00% over the past month and -60.00% over the last year.
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.